Keyword: Adaptive Biotechnologies
Amgen has tapped Adaptive Biotechnologies to deliver next-generation sequencing assays as it moves its blood cancer drugs toward approval.
Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.
The tech giant is contributing its machine learning and cloud computing capabilities, and has put skin in the game by making an equity investment.
One big challenge of using T cells to treat cancer is that each infusion contains thousands of different varieties of the cells, some of which are much more effective at killing cancer than others are. So scientists at the Fred Hutchinson Cancer Research Center in Seattle have come up with a new way to find the cells that are most likely to lead the attack against tumors.